Logo image
Back
Immediate Effects of Use of Recombinant Bone Morphogenetic Protein in Children Having Spinal Fusion and Refusion Procedures in United States
Journal article   Peer reviewed

Immediate Effects of Use of Recombinant Bone Morphogenetic Protein in Children Having Spinal Fusion and Refusion Procedures in United States

Veerasathpurush Allareddy, Veerajalandhar Allareddy, Natalia Martinez-Schlurmann, Sankeerth Rampa, R P Nalliah, K B Lidsky, A T Rotta and Satheesh Elangovan
Spine (Philadelphia, Pa. 1976), Vol.40(21), pp.1719-1726
11/2015
DOI: 10.1097/BRS.0000000000001110
PMID: 26267821

View Online

Abstract

Retrospective study of Nationwide Inpatient Sample (NIS). The objective of this study is to estimate the prevalence of complications in children who had insertion of recombinant human bone morphogenetic protein (rhBMP) at the time of spinal fusion procedures (SFP) and to examine if the use of rhBMP is associated with an increased risk of complications. Use of rhBMP for SFP has been associated with conflicting safety profile reports in adults. NIS (years 2004-2010) was used. All patients with age  < 18 years who had a SFP during hospitalization with or without insertion of rhBMP were selected. Complications were selected based on a literature review of studies examining outcomes of SFP. Association between insertion of rhBMP and occurrence of complications was examined by multivariable logistic regression models. Of the 72,898 children who underwent SFP, 7.1% children had insertion of rhBMP. Overall complication rate was 14.34% (15.2% in rhBMP group and 14.3% in no-rhBMP group). There was no statistically significant difference in the overall complication rate [odds ratio (OR) = 1.08, 95% confidence intervals (CI) = 0.89-1.30] or among 14 different complications between rhBMP and no-rhBMP groups. Children who had rhBMP were associated with higher odds for "other infections" (OR = 2.09, 95% CI = 1.26-3.48, P = 0.004) when compared with their counterparts. Despite the lack of Food and Drug Administration approval, rhBMP was not infrequently used in pediatric SFP. In this large retrospective study using administrative data, the use of rhBMP in children during SFP was not associated with higher risks for majority of assessed complications with the exception of "other infections". Future studies must examine the long-term impact of use of rhBMP in children with SFP. 3.
 Recombinant Proteins - therapeutic use Spinal Fusion - methods United States Humans Postoperative Complications - prevention & control Spinal Fusion - statistics & numerical data Child, Preschool Infant Male Treatment Outcome Postoperative Complications - epidemiology Reoperation - methods Adolescent Reoperation - statistics & numerical data Female Bone Morphogenetic Proteins - therapeutic use Retrospective Studies Postoperative Complications - drug therapy Child Infant, Newborn

Details

Metrics

7 Record Views
1 Times Cited - Web of Science
Logo image